Gerresheimer AG (GRRMF)
Market Cap | 2.19B |
Revenue (ttm) | 2.17B |
Net Income (ttm) | 81.88M |
Shares Out | n/a |
EPS (ttm) | 2.37 |
PE Ratio | 26.70 |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 872 |
Average Volume | 80 |
Open | 69.75 |
Previous Close | 69.75 |
Day's Range | 64.07 - 69.75 |
52-Week Range | 66.93 - 114.50 |
Beta | 0.94 |
RSI | 11.33 |
Earnings Date | Apr 11, 2025 |
About Gerresheimer AG
Gerresheimer AG, together with its subsidiaries, manufactures and sells medicine packaging, drug delivery devices, and solutions in Germany and internationally. It operates through three divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. The company offers prefillable syringes, plastic and glass packaging solutions, vials, glass cartridges and ampoules, bottles and containers, and glass bottles and jars, as well as caps, closures, applicators, and accessories; development, industrialization and contract manufactu... [Read more]
Financial Performance
In 2024, Gerresheimer AG's revenue was 2.04 billion, an increase of 2.28% compared to the previous year's 1.99 billion. Earnings were 109.72 million, a decrease of -5.52%.
Financial numbers in EUR Financial StatementsNews
Gerresheimer AG (GRRMF) Q1 2025 Earnings Call Highlights: Revenue Surge Amidst Organic Challenges
Gerresheimer AG (GRRMF) Q1 2025 Earnings Call Highlights: Revenue Surge Amidst Organic Challenges
Gerresheimer AG (GRRMF) Q1 2025 Earnings Call Transcript
Gerresheimer Non-GAAP EPS of Є0.46, revenue of Є520.1M; initiates FY25 outlook

Gerresheimer's first-quarter results hit by low demand in moulded glass
German packaging and medical equipment maker Gerresheimer reported a lower organic core profit for the first quarter on Friday, hit by continued lower demand in moulded glass and shift in syringe reve...

KKR drops out of consortium seeking Gerresheimer takeover, Bloomberg News reports
KKR has abandoned a private equity consortium discussing a takeover of Gerresheimer AG , Bloomberg News reported on Thursday, citing people familiar with the matter.

Exclusive: KKR, Warburg Pincus group submitted non-binding bid for Gerresheimer, sources say
A consortium including KKR and Warburg Pincus has submitted a non-binding bid for Gerresheimer AG , which makes pens used to inject weight loss drugs like Wegovy, two people with knowledge of the matt...
KKR, Warburg Picus in talks to acquire Gerresheimer - Bloomberg

Warburg Pincus, KKR in talks to buy medical packaging maker Gerresheimer, Bloomberg News reports
A consortium consisting of Warburg Pincus and KKR are in talks to acquire German medical packaging maker Gerresheimer AG , Bloomberg News reported on Wednesday citing people familiar with the matter.
Gerresheimer AG (GRRMY) Q4 2024 Earnings Call Highlights: Strong Q4 Performance Amid Strategic ...
Gerresheimer AG (GRRMY) Q4 2024 Earnings Call Highlights: Strong Q4 Performance Amid Strategic Shifts
Gerresheimer AG (GRRMF) Q4 2024 Earnings Call Transcript
Gerresheimer AG reports Q4 results

Gerresheimer slashes revenue guidance for 2025 in half
German packaging and medical equipment maker Gerresheimer halved its guidance for 2025 on Wednesday.

Gerresheimer draws interest from Phillips-Medisize and Bain, Bloomberg News reports
German medical packaging maker Gerresheimer has garnered interest from US medical solutions company Phillips-Medisize and buyout firm Bain Capital for parts or all of Gerresheimer, Bloomberg News repo...

German packaging firm Gerresheimer exploring sale, Bloomberg News reports
German medical packaging maker Gerresheimer is exploring a potential sale amid interest from private equity funds, Bloomberg News reported on Friday, citing people familiar with the matter.
Gerresheimer AG (GRRMY) Q3 2024 Earnings Call Highlights: Navigating Growth Amid Challenges
Gerresheimer AG (GRRMY) Q3 2024 Earnings Call Highlights: Navigating Growth Amid Challenges

Gerresheimer shares jump as activist investor buys over 5% stake
Gerresheimer's shares rose as much as 6.8% on Wednesday after a regulatory filing showed activist investor Ricky Chad Sandler had bought a 5.43% stake in German medical packaging maker.
Fill Finish Manufacturing Strategic Business Report 2023-2030 with Focus on 45+ Select Players Including Bausch+Strobel Maschinenfabrik Ilshofen, Becton, Dickinson and Co, & Gerresheimer Among Others – ResearchAndMarkets.com
DUBLIN — The “Fill Finish Manufacturing – Global Strategic Business Report” report has been added to ResearchAndMarkets.com’s offering. The global market for Fill Finish Manufacturing is estimated at ...

Gerresheimer AG (GRRMF) Q2 2024 Earnings Call Transcript
Gerresheimer AG (OTCPK:GRRMF) Q2 2024 Earnings Conference Call July 11, 2024 4:00 AM ET Company Participants Guido Pickert - IR Dietmar Siemssen - CEO Bernd Metzner - CFO Conference Call Participants ...

Gerresheimer core profit meets forecast on weight-loss drug deals pipeline
Germany's Gerresheimer posted second-quarter adjusted core profit in line with market expectations on Thursday, driven by the deal pipeline for its plastics and devices segment, which supplies makers ...

Gerresheimer supplies 'key players' in GLP-1 drugs market, CEO says
German packaging and medical equipment maker Gerresheimer is contracted to supply key players in the market for GLP-1 weight loss drugs, its CEO Dietmar Siemssen said on Thursday.

Gerresheimer expects sales boost from burgeoning obesity drugs sector
German packaging and medical equipment maker Gerresheimer on Thursday posted adjusted first-quarter core profit in line with expectations of analysts polled by Vara Research, driven by the plastics an...

Gerresheimer Makes Solid Start to the Financial Year 2024
Organic growth: Revenues +2.8%, adjusted EBITDA +5.9% Capacity expansion in the Americas, Europe and Asia progresses according to plan Guidance confirmed DUSSELDORF, GERMANY / ACCESSWIRE / April 11, 2...

Gerresheimer CEO dubs weight-loss drugs a meaningful positive catalyst
Dietmar Siemssen – the chief executive of Gerresheimer AG (ETR: GXI) expects strong demand for weight-loss drugs to be a meaningful tailwind for his company. Weight-loss drugs to boost $GXI revenue gr...

Weight-loss drug deals to drive around 4% of Gerresheimer yearly growth, CEO says
Gerresheimer CEO Dietmar Siemssen said he expects about 4% of the company's revenue growth per year from deals to supply makers of drugs for weight loss and diabetes with vials, cartridges, syringes a...

Gerresheimer AG (GRRMF) Q4 2023 Earnings Call Transcript
Gerresheimer AG (GRRMF) Q4 2023 Earnings Call Transcript